Stock market today: S&P 500 closes at fresh record ahead of Nvidia earnings
SOUTH SAN FRANCISCO - Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company with a market capitalization of $200 million, announced the appointment of Richard van den Broek to its board of directors today. Van den Broek, a managing partner at HSMR Advisors, brings over three decades of experience in the life sciences sector to the Corvus board. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt, positioning it well for future development initiatives.
Chairman, President, and CEO of Corvus, Richard A. Miller, M.D., expressed confidence in van den Broek's expertise in the biotechnology industry and his deep understanding of the global pharmaceutical market. The company anticipates benefiting from his insights as they progress with their lead product candidate soquelitinib, an ITK inhibitor aimed at treating cancer and immune diseases. While InvestingPro analysis indicates the company is not currently profitable, with analyst forecasts suggesting continued losses this year, the stock has shown remarkable resilience with a 73% return over the past year.
Van den Broek, who currently serves as managing partner at HSMR Advisors since February 2004, has held director positions at Pulse Biosciences and Cogstate Ltd, and was a board member at Pharmacyclics, Inc. until its acquisition by AbbVie in March 2015. He is a Harvard University alumnus and holds a Chartered Financial Analyst designation.
Corvus Pharmaceuticals focuses on pioneering ITK inhibition as a novel immunotherapy approach for a broad spectrum of cancers and immune diseases. The company's clinical pipeline continues to advance, with soquelitinib at the forefront as an investigational oral drug.
The appointment of Mr. van den Broek to the board is based on a press release statement from Corvus Pharmaceuticals. This addition to the board is expected to contribute to the company's strategic direction as they navigate the complexities of the biopharmaceutical industry. With analyst price targets ranging from $11 to $24, significantly above the current trading price, investors can find additional valuable insights and real-time metrics through InvestingPro's comprehensive coverage.
In other recent news, Corvus Pharmaceuticals reported a wider-than-expected loss for the fourth quarter of 2024, with an earnings per share (EPS) of -$0.18, missing analyst forecasts of -$0.12. The company reported a net loss of $12.1 million for the quarter, reflecting increased expenses and strategic investments in its product pipeline. Despite the widened loss, Corvus maintains a strong cash position, with $52 million in cash and cash equivalents, which is expected to sustain operations into the first quarter of 2026. H.C. Wainwright reaffirmed their positive stance on Corvus, reiterating a Buy rating with a price target of $11.00, highlighting confidence in the company's financial stability and strategic planning. The firm anticipates that Corvus will continue to operate without generating revenue in 2025 and projects a net loss of $0.43 per share. Key developments in Corvus's product pipeline include promising trial results for sokolitinib, which were discussed during the earnings call. The company outlined several milestones for 2025, including the presentation of atopic dermatitis data and the initiation of a solid tumor trial. CEO Richard Miller expressed optimism about the company's future, emphasizing the potential of sokolitinib in treating immune diseases and cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.